To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
Recruiting · NCT07149571 · Observational (researchers observe without assigning treatment) · Lead sponsor: Tongji Hospital
View the official record on ClinicalTrials.gov →What this trial is about
The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease. By obtaining clinical, imaging, laboratory examination and pathological data of metabolism-related fatty liver disease, image processing software is used to analyze the images, explore the relationship between imaging parameters, body composition and metabolic diseases and metabolism-related fatty liver disease, and achieve non-invasive diagnosis, efficacy evaluation, and prognosis prediction of metabolism-related fatty liver disease. Thereby guiding clinical treatment and improving the prognosis and quality of life of patients with metabolism-related fatty liver disease
Who can take part
Inclusion criteria
- Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease;
- Age/gender: unlimited;
- Patients who voluntarily participate in clinical trials and sign written subject informed consent
Exclusion criteria
- Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination;
- Voluntarily participation in the study and provision of written informed consent.
Where it is running
1 location listed.
- Tongji hospital - Wuhan, Hubei, China